Global Healthcare Analyst

Tina Banerjee

Equity research analyst having 15+ years of experience, with an interest on fundamentally strong global healthcare companies. I have been helping investors to find future winners in healthcare space to grow their wealth by focusing on the strength and potential of the business models of the companies. My initiating coverage reports and pitch help investors to know ‘what to buy’, ‘why to buy’, and ‘when to buy’. My clients always remain on top of the sector with the help of my timely and detailed notes on earnings or any news update. I also provide broader view on the entire healthcare sector through periodic thematic reports.

Equity Capital Markets

BioRay Biopharmaceutical / Equity Capital Markets

<ul>
<li>BioRay Biopharmaceutical has filed for Hongkong IPO. It is a leading biopharmaceutical company, providing immunological therapeutic solutions across autoimmune and inflammatory diseases, immuno-oncology and malignancies of immune system itself.</li>
<li>BioRay Biopharmaceutical intends to use the IPO proceeds for commercialization of innovative products, R&amp;D of pipeline products, development of the technology platforms, funding potential investments, strengthen operational capabilities etc.</li>
<li>For now, we feel there is a chance that the company may face some medium-term growth hurdles with the existing product portfolio at hand.</li>
</ul>


BioRay Biopharmaceutical has filed for Hongkong IPO. It is a leading biopharmaceutical company, providing immunological therapeutic solutions across autoimmune and inflammatory diseases, immuno-oncology and malignancies of immune system itself.
BioRay Biopharmaceutical intends to use the IPO proceeds for commercialization of innovative products, R&amp;D of pipeline products, development of the technology platforms, funding potential investments, strengthen operational capabilities etc.
For now, we feel there is a chance that the company may face some medium-term growth hurdles with the existing product portfolio at hand.


BioRay Biopharmaceutical Pre IPO: Not Immune to Future Growth Hurdles